Nightstar Therapeutics Ltd.

General Information
Business:

We are a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Leveraging our expertise in ophthalmology, gene therapy and drug development, we are developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES
Employees: 23
Founded: 2013
Contact Information
Address 215 Euston Road, London NW1 2BE, United Kingdom
Phone Number +44 20 7611 2077
Web Address http://www.nightstartx.com
View Prospectus: Nightstar Therapeutics Ltd.
Financial Information
Market Cap $393.4mil
Revenues $0 mil (last 12 months)
Net Income $-12.9 mil (last 12 months)
IPO Profile
Symbol NITE
Exchange NASDAQ
Shares (millions): 5.4
Price range $14.00 - $14.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Jefferies/ Leerink Partners/ BMO Capital Markets
CO-Managers Wedbush PacGrow/ Chardan
Expected To Trade: 9/28/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change